8-K: Modular Medical Prices $3.4M Direct Offering

Modular Medical, Inc. announced the pricing of a registered direct offering of 750,000 shares of common stock, raising approximately $3.4 million.

Summary

• Modular Medical, Inc. has entered into a Placement Agency Agreement with Maxim Group LLC for a registered direct offering.
• The offering involves 750,000 shares of common stock at an offering price of $4.50 per share.
• The gross proceeds are approximately $3.375 million before fees and expenses.
• The offering is expected to close on April 21, 2026.
• The company will pay a 7% cash fee to the placement agent and reimburse expenses up to $75,000.
• Directors and executive officers have entered into 90-day lock-up agreements.
• The company has agreed not to issue additional stock or equivalents for 45 days post-closing, with certain exceptions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it provides necessary capital, it also involves dilution and significant fees, with the ultimate success depending on the company's execution.

Positives

• Successful pricing of a registered direct offering, raising approximately $3.4 million in gross proceeds.
• The offering is made under an effective Form S-3 registration statement, indicating prior SEC review.
• The company has secured a placement agent, Maxim Group LLC, to facilitate the offering.
• Lock-up agreements are in place for directors and executive officers, potentially signaling confidence and stability.

Negatives

• The offering dilutes existing shareholders due to the issuance of new shares.
• The company incurs significant fees (7%) and expense reimbursements ($75,000) to the placement agent.
• A 45-day lock-up on the company's ability to issue further stock could limit future capital raising flexibility in the short term.

Risks

• The actual closing of the offering is subject to customary closing conditions.
• The company's ability to convert patients to its Pivot pump product is a key risk.
• Successful development and market acceptance of Modular Medical's proprietary technologies are not guaranteed.
• General economic, industry, or political conditions could impact the company's performance.

Future Outlook

The company is pursuing a registered direct offering to raise capital. Forward-looking statements in the press release indicate potential risks related to product conversion, market acceptance, and general economic conditions.

Management Comments

• Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the pricing of a registered direct offering (the Offering) consisting of 750,000 shares of the Companys common stock at an offering price of $4.50 per share.
• The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses.
• The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
• Maxim Group LLC is acting as the sole placement agent in connection with the Offering.

Industry Context

StockSavvy.ai notes that capital raises via registered direct offerings are common for smaller, growth-oriented companies in the medical device sector, particularly those seeking to fund product development, commercialization, or expansion. This move by Modular Medical aligns with industry trends where companies leverage public markets to secure necessary funding for innovation and market penetration.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Investors participating in the offering will acquire new shares at $4.50 each.
• Maxim Group LLC will receive fees and expense reimbursements for its role as placement agent.

Next Steps

• Closing of the registered direct offering on or about April 21, 2026.
• Post-closing, the company will be subject to a 45-day restriction on issuing additional stock or equivalents, with exceptions.
• Directors and executive officers are subject to 90-day lock-up agreements.

Key Dates

Recommendation

The capital raise provides necessary funding but also dilutes existing shareholders. The company's future success hinges on its ability to execute its product strategy, making it a hold until further operational progress is demonstrated.

Keywords

Modular Medical, MODD, Registered Direct Offering, Common Stock, Maxim Group LLC, Form S-3, Capital Raise, Medical Device